Showing results (31-40 of 304) with videos related to
Sort By:
Pageof 31
The Lancet. Oncology|February 28, 2017
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based studyDaniel M Halperin, Chan Shen, Arvind Dasari, et al.BMC Bioinformatics|March 24, 2022
On Bayesian modeling of censored data in JAGSXinyue Qi, Shouhao Zhou, Martyn PlummerElife|August 3, 2022
Robust and Efficient Assessment of Potency (REAP) as a quantitative tool for dose-response curve estimationShouhao Zhou, Xinyi Liu, Xinying Fang, et al.Pancreas|November 6, 2019
Racial Differences in the Incidence and Survival of Patients With Neuroendocrine TumorsChan Shen, Dian Gu, Shouhao Zhou, et al.Journal of Clinical and Translational Science|November 29, 2023
REAP-2: An interactive quantitative tool for robust and efficient dose-response curve estimationXinying Fang, Xinyi Liu, Vernon M Chinchilli, et al.Journal of the American Statistical Association|December 15, 2025
Posterior Predictive Design for Phase I Clinical TrialsChenqi Fu, Shouhao Zhou, J Jack LeePharmacoeconomics|April 24, 2018
Costs of Cancer Care for Elderly Patients with Neuroendocrine TumorsChan Shen, Arvind Dasari, Dian Gu, et al.Cancer Medicine|April 5, 2019
Impact of serious mental illness on the treatment and mortality of older patients with locoregional high-grade (nonmetastatic) prostate cancer: retrospective cohort analysis of 49 985 SEER-Medicare patients diagnosed between 2006 and 2013Dennis A Fried, Hossein Sadeghi-Nejad, Dian Gu, et al.Pharmaceutical Statistics|March 7, 2023
Covariate handling approaches in combination with dynamic borrowing for hybrid control studiesChenqi Fu, Herbert Pang, Shouhao Zhou, et al.Research Synthesis Methods|September 2, 2022
Bayesian sparse modeling to identify high-risk subgroups in meta-analysis of safety dataXinyue Qi, Shouhao Zhou, Yucai Wang, et al.Pageof 31